Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group-Reference-Cited by-同舟云学术

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

Published:2017-02-15 Issue:2 Volume:18 Page:415
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Pleyer Lisa,Döhner Hartmut,Dombret Hervé,Seymour John,Schuh Andre,Beach CL,Swern Arlene,Burgstaller Sonja,Stauder Reinhard,Girschikofsky Michael,Sill Heinz,Schlick Konstantin,Thaler Josef,Halter Britta,Machherndl Spandl Sigrid,Zebisch Armin,Pichler Angelika,Pfeilstöcker Michael,Autzinger Eva,Lang Alois,Geissler Klaus,Voskova Daniela,Sperr Wolfgang,Hojas Sabine,Rogulj Inga,Andel Johannes,Greil Richard

Funder

Celgene

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/2/415/pdf

Reference61 articles.

1. Acute Myelogenous Leukemia in Older Adults

2. Age and acute myeloid leukemia

3. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

4. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

5. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

2. Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study);Leukemia Research Reports;2024

3. New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment – An oncogeriatric perspective;Journal of Geriatric Oncology;2023-09

4. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT;American Journal of Hematology;2023-08-07

5. Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group;Cancers;2023-04-14